To: 5.1.2e [5.1.2e @curevac.com]; 5.1.2e [5.1.2e @curevac.com]; 5.1.2e 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e [5.1.2e @bayer.com]; 5.1.2e [5.1.2e @bayer.com]; 5.1.2e [5.1.2e @bayer.com]; 5.1.2e [5.1.2e @bayer.com]
Cc: 5.1.2e [5.1.2e @bayer.com]; 5.1.2e [5.1.2e @bayer.com]; 5.1.2e 5.1.2e [5.1.2e @bayer.com]; 5.1.2e [5.1.2e @curevac.com]
From: 5.1.2e
Sent: Wed 2/17/2021 12:43:09 PM
Subject: AW: Follow-up MoH Netherlands
Received: Wed 2/17/2021 12:44:55 PM
Presentation MoH Netherlands_20210216.pdf
smime.p7s

Dear 5.1.2e and Team,

Thank you for the meeting today. As discussed please find attached the shared presentation to you reference.
As discussed there will be an update to all member states on 5.1.5 were we will share a broader update on stability, distribution quantities, frequencies and times. Beside that we discussed the following:

- 5.1.1c
- We´re in discussion with the EMA about all aspects of label and label exceptions and will come back to member states when having clarity here.
- 5.1.1c
- We learned that the Netherlands doesn´t requires PIL in paper form at all.
- We confirm that our current clinical program doesn´t limit the usage of our vaccine to people below 65
- Subject to availability, a follow-up call will be held on March 11th, 1pm

Mit freundlichen Grüßen / With best regards
5.1.2e

CureVac AG
Tübingen
t: +49 5.1.2e
f: +49
e: 5.1.2e @curevac.com